IRWD Q4 2024 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$91M-23.0% YoY

Gross Profit

$91M100.0% margin

Operating Income

$31M34.8% margin

Net Income

$2M2.5% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$15M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$351M

Total Liabilities

$652M

Stockholders' Equity

-$301M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$91M	$118M	-23.0%
Gross Profit	$91M	$118M	-23.0%
Operating Income	$31M	$38M	-16.2%
Net Income	$2M	-$1M	+307.5%

Revenue Segments

Collaborative arrangement, collaboration and license agreements

$892,000100%

Geographic Segments

North America

$181M99%

Europe and Other

$2M1%